A Patient with Recurrent Pleural Effusion and Negative Cytology: A Case-Based Approach to Diagnosing Pleural Lymphoma

Author Name : Hidoc internal team

Oncology

Page Navigation

Abstract

Recurrent pleural effusion with repeatedly negative cytology presents a substantial diagnostic challenge, particularly when imaging demonstrates pleural thickening, nodularity, or progressive fluid accumulation. Although malignant pleural effusion is frequently attributed to metastatic carcinoma or mesothelioma, pleural lymphoma is an important and potentially treatable differential diagnosis. Cytological examination may be nondiagnostic because lymphoma cells can be sparse, fragile, obscured by reactive inflammatory cells, or difficult to classify without flow cytometry and tissue architecture. This review presents a case-based diagnostic framework for suspected pleural lymphoma, emphasizing disease burden, pathophysiology, clinical manifestations, limitations of conventional testing, and the role of image-guided pleural biopsy, thoracoscopy, immunophenotyping, molecular studies, and systemic staging. A coordinated approach involving pulmonology, radiology, pathology, hematology, and oncology is essential. Early tissue acquisition can prevent repeated low-yield thoracenteses and accelerate disease-specific treatment.

Introduction

A patient with recurrent unilateral pleural effusion and negative cytology requires reassessment rather than reassurance. Pleural fluid cytology is valuable for detecting many metastatic adenocarcinomas, but its sensitivity varies substantially by tumor type and burden. Lymphoma is especially challenging because malignant lymphoid cells may resemble reactive lymphocytes, may not survive specimen processing, and often require immunophenotypic confirmation. A negative cytology result therefore excludes neither lymphoma nor other pleural malignancies when clinical and radiological suspicion remains high. The diagnostic objective is to identify the cause of the effusion, establish histological subtype, determine the extent of disease, and assess whether the process is curable, controllable, or associated with an underlying systemic disorder.

Epidemiology / Disease Burden

Pleural involvement occurs most commonly in systemic malignancies, infection, heart failure, and inflammatory disease. Primary effusion lymphoma is uncommon and classically associated with human herpesvirus 8, immunodeficiency, and fluid accumulation in body cavities without a dominant mass. More frequently, pleural disease reflects secondary involvement by non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and T-cell neoplasms. Lymphomatous pleural effusions may develop through direct pleural infiltration, lymphatic obstruction, thoracic duct disruption, mediastinal nodal disease, or cytokine-driven vascular permeability. Disease burden is clinically important because recurrent effusion can cause dyspnea, impaired mobility, reduced functional status, repeated hospital visits, and delays in systemic therapy. The incidence of lymphoma-related pleural involvement is difficult to quantify because it is often reported within broader categories of malignant effusion.

Pathophysiology

Pleural lymphoma develops when malignant lymphoid cells infiltrate the pleura, mediastinal lymph nodes, or lymphatic drainage pathways. Obstruction of parietal pleural lymphatics reduces fluid clearance, while tumor-associated inflammation increases endothelial permeability and promotes exudate formation. Chylous effusion may occur when lymphoma compresses or invades the thoracic duct. In primary effusion lymphoma, viral oncogenesis and immune dysfunction contribute to the accumulation of malignant cells in serous cavities. The cellular appearance of lymphoma in pleural fluid may be altered by degeneration, reactive mesothelial proliferation, and a mixed inflammatory background. Consequently, morphology alone may be insufficient. Flow cytometry can demonstrate clonality and aberrant antigen expression, whereas core tissue permits evaluation of architecture, immunohistochemistry, proliferation indices, cytogenetics, and molecular alterations needed for classification and treatment selection.

Risk Factors

Risk factors include advanced age, previous or active hematologic malignancy, immunosuppression, human immunodeficiency virus infection, transplantation, autoimmune disease treated with immunomodulatory agents, and chronic viral infections such as Epstein-Barr virus or human herpesvirus 8 in relevant disease settings. Prior chemotherapy or radiotherapy may increase the likelihood of secondary malignancy, although treatment-related effects must be distinguished from recurrent lymphoma. Constitutional symptoms, unexplained lymphadenopathy, elevated lactate dehydrogenase, cytopenias, or disproportionate systemic inflammation should increase suspicion. A history of recurrent unexplained exudative effusion, especially when associated with pleural nodularity or mediastinal adenopathy, warrants tissue diagnosis even when cytology remains negative.

Clinical Features

Patients commonly present with progressive exertional dyspnea, pleuritic chest pain, cough, fatigue, fever, night sweats, or unintentional weight loss. Some have only recurrent fluid accumulation without prominent systemic symptoms. Examination may reveal reduced breath sounds, dullness to percussion, asymmetric chest expansion, peripheral lymphadenopathy, splenomegaly, or signs of superior vena cava obstruction. Pleural fluid is usually exudative, although exceptions occur in patients with coexisting cardiac, hepatic, or renal disease. Lymphocyte predominance may suggest lymphoma but is not diagnostic. A bloody effusion can occur with malignancy, pulmonary embolism, or trauma, while chylothorax should prompt measurement of triglycerides and assessment for thoracic duct obstruction. Clinical deterioration after temporary relief from repeated drainage should prompt a change from symptom-focused management to definitive diagnostic evaluation.

Diagnosis

Evaluation begins with a complete history, physical examination, chest radiography, and contrast-enhanced computed tomography. CT findings that raise concern include circumferential pleural thickening, pleural nodules, fissural involvement, mediastinal or hilar lymphadenopathy, chest-wall invasion, and an effusion disproportionate to other findings. Positron emission tomography combined with CT can identify metabolically active pleural and extrathoracic sites and guide biopsy, although inflammatory disease can produce false-positive uptake. Thoracic ultrasound is useful for characterizing fluid, detecting septations, and selecting a safe sampling site.

Diagnostic thoracentesis should include cell count and differential, protein and lactate dehydrogenase measurements, glucose, pH when infection is considered, microbiological studies when appropriate, and cytological examination. When lymphoma is suspected, a fresh fluid sample should be sent promptly for flow cytometry in an anticoagulant tube, with adequate volume and communication between the clinical team and laboratory. Flow cytometry may identify a monoclonal B-cell population or aberrant T-cell phenotype, but a negative result does not exclude lymphoma if the sample is paucicellular, necrotic, improperly handled, or derived from a tumor subtype with limited shedding. Pleural fluid cell-block preparation enables immunohistochemistry but may still lack architectural information.

Persistent clinical suspicion after nondiagnostic fluid studies should lead to image-guided core needle biopsy or medical thoracoscopy. Thoracoscopy permits direct inspection of the pleura and multiple targeted biopsies, generally providing greater diagnostic yield than repeated blind sampling. Histopathology should be integrated with immunohistochemical markers, including B-cell, T-cell, plasma-cell, and activation markers as clinically indicated. Ancillary studies may include clonality assays, fluorescence in situ hybridization, next-generation sequencing, viral studies, and assessment of MYC, BCL2, BCL6, or other alterations relevant to lymphoma classification. Bone marrow evaluation and systemic staging with PET-CT, laboratory testing, and selected central nervous system assessment are guided by the suspected subtype and clinical findings.

Treatment & Management

Management depends on histological subtype, stage, performance status, comorbidities, immune status, and treatment goals. The underlying lymphoma should be treated as the primary cause of the effusion. For aggressive B-cell lymphoma, combination immunochemotherapy based on an anti-CD20 antibody and an anthracycline-containing regimen remains a common foundation, although regimen selection must be individualized. Indolent lymphomas may be managed with observation in selected asymptomatic patients, anti-CD20 therapy, combination treatment, or radiotherapy when localized. T-cell lymphomas, primary effusion lymphoma, and immunodeficiency-associated disease require subtype-specific strategies and infectious disease management when relevant.

Supportive pleural care includes therapeutic thoracentesis for symptomatic relief, correction of hypoxemia, nutritional and functional support, and treatment of infection or thrombosis when present. Repeated drainage alone is not definitive therapy. In patients with persistent symptomatic recurrence despite systemic treatment, indwelling pleural catheter placement or chemical pleurodesis may be considered after evaluating lung re-expansion, prognosis, infection risk, and patient preference. Chylous effusion may require dietary modification, drainage, and management of thoracic duct obstruction. The risk of bleeding, pneumothorax, infection, re-expansion pulmonary edema, catheter complications, and treatment-related immunosuppression should be discussed explicitly.

Recent Advances / Emerging Therapies

Advances in lymphoma classification increasingly integrate morphology with molecular and genomic data, improving recognition of biologically distinct diseases that may appear similar in pleural fluid. Highly sensitive flow cytometry, digital pathology, circulating tumor DNA, and targeted sequencing may help identify clonality or treatment-relevant alterations when tissue is limited, although these approaches do not universally replace biopsy. Novel therapies include antibody-drug conjugates, bispecific antibodies, selective kinase inhibitors, immunomodulatory agents, and chimeric antigen receptor T-cell therapy for selected relapsed or refractory lymphomas. Antiviral therapy and restoration of immune function may be important in virus-associated disease. Clinical trial enrollment should be considered whenever standard therapy is unsuitable, the disease is refractory, or an emerging targeted approach is biologically appropriate.

Guideline Recommendations

Current guideline-based principles support obtaining tissue when recurrent exudative effusion remains unexplained after initial evaluation or when imaging suggests pleural malignancy. Cytology should not be treated as a definitive exclusion test for lymphoma. Specimens should be triaged prospectively for cytology, cell block, flow cytometry, microbiology, and molecular testing according to the differential diagnosis. Image-guided biopsy or thoracoscopy is recommended when fluid studies are nondiagnostic and suspicion persists. Confirmed lymphoma should be classified according to contemporary hematopathology criteria and staged with appropriate imaging and laboratory assessment. Multidisciplinary review is particularly important because pleural sampling, pathological interpretation, systemic therapy, and symptom control require coordinated decisions. Follow-up should assess effusion recurrence, treatment response, functional status, infection risk, and patient-reported symptoms.

Conclusion

Recurrent pleural effusion with negative cytology is a diagnostic warning sign when accompanied by pleural abnormalities, lymphadenopathy, constitutional symptoms, or persistent recurrence. Pleural lymphoma may be missed because malignant lymphoid cells are fragile, sparse, or morphologically indistinguishable from reactive lymphocytes. Early incorporation of flow cytometry, cell-block immunophenotyping, advanced imaging, and adequately obtained pleural tissue can substantially shorten the diagnostic pathway. Once the lymphoma subtype is established, systemic treatment should be directed by disease biology and patient fitness, while pleural interventions provide symptom relief and preserve quality of life. A structured, multidisciplinary, tissue-centered approach is essential for accurate diagnosis and timely treatment.

Featured News
Featured Articles
Featured Events
Featured KOL Videos

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot